Search ARM

Aposcience AG was founded in 2008 in order to foster research in Peripheral Blood Mononuclear Cells (PBMC) secretome. In 2014-16 the first PBMC secretome-based clinical phase I trial was concluded (Eudract-Number: 2013-000756-17). In 2014 Aposcience established a GMP-validated production site and has the allowance to produce our product, APOSEC, as investigational drug product (IMP) for clinical phase I-III studies in humans. The first allogeneic secretome-based therapy in diabetic foot ulcer (phase II) was approved in December 2019. Secretome-based therapy does not fit into any currently accepted category by the Alliance of Regenerative Medicine.

Contact Aposcience AG
Visit Website